Vaishali Parab
Overview
Explore the profile of Vaishali Parab including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
83
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stransky L, Gao W, Schmidt L, Bi K, Ricketts C, Ramesh V, et al.
Proc Natl Acad Sci U S A
. 2024 Oct;
121(41):e2408549121.
PMID: 39365820
CRISPR is revolutionizing the ability to do somatic gene editing in mice for the purpose of creating new cancer models. Inactivation of the tumor suppressor gene is the signature initiating...
2.
Erfani A, Schieferstein J, Reichert P, Narasimhan C, Pastuskovas C, Parab V, et al.
Adv Healthc Mater
. 2023 Feb;
12(15):e2202370.
PMID: 36745878
Subcutaneous (SC) administration is a desired route for monoclonal antibodies (mAbs). However, formulating mAbs for small injection volumes at high concentrations with suitable stability and injectability is a significant challenge....
3.
Cowan K, Gao X, Parab V, Nguy T, Wu L, Arron J, et al.
Bioanalysis
. 2016 Oct;
8(22):2329-2340.
PMID: 27712082
Aim: To improve on the efficiency of biomarker assay readiness, and for reliable biomarker data to support three drug programs, we implemented a fit-for-purpose approach, qualifying two biomarker assays and...
4.
Koeppen H, Yu W, Zha J, Pandita A, Penuel E, Rangell L, et al.
Clin Cancer Res
. 2014 Apr;
20(17):4488-98.
PMID: 24687921
Purpose: In a recent phase II study of onartuzumab (MetMAb), patients whose non-small cell lung cancer (NSCLC) tissue scored as positive for MET protein by immunohistochemistry (IHC) experienced a significant...
5.
Penuel E, Li C, Parab V, Burton L, Cowan K, Merchant M, et al.
Mol Cancer Ther
. 2013 Mar;
12(6):1122-30.
PMID: 23536720
The objective of this study was to evaluate circulating hepatocyte growth factor (cHGF) as a pharmacodynamic biomarker of Met inhibition for onartuzumab (MetMAb, OA5D5v2) in a phase I trial in...